Determinants of worse liver-related outcome according to HDV infection among HBsAg positive persons living with HIV: Data from the ICONA cohort.
Delta infection
HBV infection
HCV infection
HIV infection
death
immunodepression
severe liver disease
Journal
Liver international : official journal of the International Association for the Study of the Liver
ISSN: 1478-3231
Titre abrégé: Liver Int
Pays: United States
ID NLM: 101160857
Informations de publication
Date de publication:
15 Dec 2023
15 Dec 2023
Historique:
revised:
30
10
2023
received:
28
09
2023
accepted:
12
11
2023
medline:
15
12
2023
pubmed:
15
12
2023
entrez:
15
12
2023
Statut:
aheadofprint
Résumé
We aimed to study hepatitis D virus (HDV) prevalence and risk of progression to severe liver-related events (SLRE) in HBsAg positive people living with HIV (PLWH) in Italy; role of HDV-RNA copy levels, HCV coinfection and nadir CD4 counts were also investigated. People living with HIV (PLWH) from Italian Foundation cohort Naïve antiretrovirals (ICONA) with available HBsAg and HDV Ab were enrolled. HBsAg, HDV Ab, HDV-RNA and HDV genotypes were tested. time from first HDV screening to Severe Liver Related Events (SLRE: decompensated cirrhosis, liver transplantation, HCC). Fine-grey regression models were used to evaluate the association of HDV Ab, HDV-RNA, HDV/HCV coinfection, CD4 nadir and outcome. Secondary end-points: time to SLRE or death; HDV Ab and HDV-RNA prevalence. A total of 152/809 (18.8%) HBsAg positive PLWH showed HDV Ab reactivity; 63/93 (67.7%) were HDV-RNA positive. Being male, persons who inject drugs (PWID), HCV Ab positive, with FIB-4 > 3.25 were independent factors of HDV Ab positivity. In a median follow-up of 5 years, 37 PLWH (4.1% at 5-year) developed SLRE and 97 (12.0%) reached the SLRE or death end-point. HDV-RNA positive (independently from HDV-RNA copy level) PLWH had a 4.6-fold (95%CI 2.0-10.5) higher risk of SLRE than HDV negatives. PLWH positive for both HCV Ab and HDV Ab showed the highest independent risk of SLRE (ASHR: 11.9, 95%CI: 4.6-30.9 vs. HCV neg/HDV neg). Nadir CD4 < 200/mL was associated with SLRE (ASHR: 3.9, 95% 1.0-14.5). One-fifth of the HBsAg positive PLWH harbour HDV infection, and are at high risk of progression to advanced liver disease. HCV contributes to worse outcomes. This population needs urgently effective treatments.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Gilead Sciences
Investigateurs
A d'Arminio Monforte
(A)
A Antinori
(A)
S Antinori
(S)
A Castagna
(A)
R Cauda
(R)
G Di Perri
(G)
E Girardi
(E)
R Iardino
(R)
A Lazzarin
(A)
G C Marchetti
(GC)
C Mussini
(C)
E Quiros-Roldan
(E)
L Sarmati
(L)
B Suligoi
(B)
F von Schloesser
(F)
P Viale
(P)
A d'Arminio Monforte
(A)
A Antinori
(A)
A Castagna
(A)
F Ceccherini-Silberstein
(F)
A Cingolani
(A)
A Cozzi-Lepri
(A)
E Girardi
(E)
A Gori
(A)
S Lo Caputo
(S)
G Marchetti
(G)
F Maggiolo
(F)
C Mussini
(C)
M Puoti
(M)
C F Perno
(CF)
A Antinori
(A)
F Bai
(F)
A Bandera
(A)
S Bonora
(S)
A Calcagno
(A)
D Canetti
(D)
A Castagna
(A)
F Ceccherini-Silberstein
(F)
A Cervo
(A)
S Cicalini
(S)
A Cingolani
(A)
P Cinque
(P)
A Cozzi-Lepri
(A)
A d'Arminio Monforte
(A)
A Di Biagio
(A)
R Gagliardini
(R)
A Giacomelli
(A)
E Girardi
(E)
N Gianotti
(N)
A Gori
(A)
G Guaraldi
(G)
S Lanini
(S)
G Lapadula
(G)
M Lichtner
(M)
A Lai
(A)
S Lo Caputo
(S)
G Madeddu
(G)
F Maggiolo
(F)
V Malagnino
(V)
G Marchetti
(G)
C Mussini
(C)
S Nozza
(S)
C F Perno
(CF)
S Piconi
(S)
C Pinnetti
(C)
M Puoti
(M)
E Quiros Roldan
(E)
R Rossotti
(R)
S Rusconi
(S)
M M Santoro
(MM)
A Saracino
(A)
L Sarmati
(L)
V Spagnuolo
(V)
N Squillace
(N)
V Svicher
(V)
L Taramasso
(L)
A Vergori
(A)
F Bovis
(F)
A Cozzi-Lepri
(A)
S De Benedittis
(S)
I Fanti
(I)
A Rodano'
(A)
M Ponzano
(M)
A Tavelli
(A)
A Bove
(A)
M Cernuschi
(M)
L Cosmaro
(L)
M Errico
(M)
A Perziano
(A)
V Calvino
(V)
S Carrara
(S)
S Graziano
(S)
G Prota
(G)
S Truffa
(S)
D Vincenti
(D)
Y D'Errico
(Y)
R Rovito
(R)
A Giacometti
(A)
A Costantini
(A)
V Barocci
(V)
A Saracino
(A)
C Santoro
(C)
E Milano
(E)
L Comi
(L)
C Suardi
(C)
P Viale
(P)
L Badia
(L)
S Cretella
(S)
E M Erne
(EM)
A Pieri
(A)
E Quiros Roldan
(E)
E Focà
(E)
C Minardi
(C)
B Menzaghi
(B)
C Abeli
(C)
L Chessa
(L)
F Pes
(F)
P Maggi
(P)
L Alessio
(L)
B Cacopardo
(B)
B Celesia
(B)
J Vecchiet
(J)
K Falasca
(K)
A Pan
(A)
S Dal Zoppo
(S)
D Segala
(D)
M A Di Pietro
(MA)
C Costa
(C)
S Lo Caputo
(S)
S Ferrara
(S)
M Bassetti
(M)
E Pontali
(E)
S Blanchi
(S)
N Bobbio
(N)
G Mazzarello
(G)
M Lichtner
(M)
L Fondaco
(L)
S Piconi
(S)
C Molteni
(C)
S Rusconi
(S)
G Canavesi
(G)
G Nunnari
(G)
G Pellicanò
(G)
G Marchetti
(G)
S Antinori
(S)
G Rizzardini
(G)
M Puoti
(M)
A Castagna
(A)
A Bandera
(A)
V Bono
(V)
M V Cossu
(MV)
A Giacomelli
(A)
R Lolatto
(R)
M C Moioli
(MC)
L Pezzati
(L)
S Diotallevi
(S)
C Tincati
(C)
C Mussini
(C)
C Puzzolante
(C)
P Bonfanti
(P)
G Lapadula
(G)
V Sangiovanni
(V)
I Gentile
(I)
V Esposito
(V)
N Coppola
(N)
F M Fusco
(FM)
G Di Filippo
(G)
V Rizzo
(V)
N Sangiovanni
(N)
S Martini
(S)
A M Cattelan
(AM)
D Leoni
(D)
A Cascio
(A)
C Colomba
(C)
D Francisci
(D)
E Schiaroli
(E)
G Parruti
(G)
F Sozio
(F)
P Blanc
(P)
S I Bonelli
(SI)
C Lazzaretti
(C)
R Corsini
(R)
A Antinori
(A)
R Cauda
(R)
C Mastroianni
(C)
L Sarmati
(L)
A Latini
(A)
A Cingolani
(A)
V Mazzotta
(V)
S Lamonica
(S)
M Capozzi
(M)
A Mondi
(A)
M Rivano Capparuccia
(M)
G Iaiani
(G)
C Stingone
(C)
L Gianserra
(L)
J Paulicelli
(J)
M M Plazzi
(MM)
G d'Ettore
(G)
M Fusto
(M)
I Coledan
(I)
G Madeddu
(G)
A De Vito
(A)
M Fabbiani
(M)
F Montagnani
(F)
A Franco
(A)
R Fontana Del Vecchio
(R)
B M Pasticci
(BM)
C Di Giuli
(C)
G C Orofino
(GC)
G Calleri
(G)
G Di Perri
(G)
S Bonora
(S)
G Accardo
(G)
C Tascini
(C)
A Londero
(A)
V Manfrin
(V)
G Battagin
(G)
G Starnini
(G)
D Farinacci
(D)
Informations de copyright
Liver International© 2023 The Authors. Liver International published by John Wiley & Sons Ltd.
Références
Rizzetto M, Canese MG, Aricò S, et al. Immunofluorescence detection of a new antigen-antibody system (delta/anti-delta) associated with hepatitis B virus in liver and in serum of HBsAg carriers. Gut. 1977;18:997-1003.
Smedile A, Rizzetto M, Gerin JL. Advances in hepatitis D virus biology and disease. In: Boyer JL, Ockner RK, eds. Progress in Liver Disease. Vol Xii. W.B. Saunders Company; 1994:157-175.
Brancaccio G, Coco B, Nardi A, et al. PITER collaborating investigators. Trends in chronic hepatitis B virus infection in Italy over a 10-year period: clues from the nationwide PITER and MASTER cohorts toward elimination. Int J Infect Dis. 2023;13(129):266-273.
Chen H-Y, Shen D-T, Ji D-Z, et al. Prevalence and burden of hepatitis D virus infection: systematic review and meta-analysis. Gut. 2019;68(3):512-521.
Brancaccio G, Shanyinde M, Puoti M, et al. Hepatitis delta coinfection in persons with HIV: misdiagnosis and disease burden in Italy. Pathog Glob Health. 2022;7:1-9. doi:10.1080/20477724.2022.2047551
Beguelin C, Atkinson A, Boyd A, et al. Hepatitis delta infection among persons living with HIV in Europe. Liver Int. 2023;43:819-828.
Castellares C, Barreiro P, Martín-Carbonero L, et al. Liver cirrhosis in HIV-infected patients: prevalence, aetiology and clinical outcome. J Viral Hepat. 2008;15:165-172.
Fernandez-Montero JV, Vispo E, Barreiro P, et al. Hepatitis delta is a major determinant of liver decompensation events and death in HIV-infected patients. Clin Infect Dis. 2014;58(11):1549-1553.
Soriano V, Sherman K, Barreiro P. Hepatitis delta and HIV infection. AIDS. 2017;31(7):875-884.
Kamal H, Westman G, Falconer K, et al. Long-term study of hepatitis D infection at secondary care centers: the impact of viremia on liver-related outcomes. Hepatology. 2020;72:1177-1190.
Ricco G, Cavallone D, Colombatto P, et al. HDV RNA levels <1000 IU/mL and total anti-HDV titers <1:1000 identify chronic hepatitis D subjects without active liver disease. J Hepatology. 2023;78(S1):S1091.
Yurdaydin C, Abbas Z, Buti M, et al. Treating chronic hepatitis delta: the need or surrogate markers of treatment efficacy. J Hepatol. 2019;70:1008-1015.
D'Arminio Monforte A, Cozzi-Lepri A, Rezza G, et al. Insight into the Reasons for Discontinuation of the First Highly Active Antiretroviral Therapy (HAART) Regimen in a Cohort of Antiretroviral naïve Patients. AIDS. 2000;14:499-507.
De Socio GV, Ricci E, Bonfanti P, Quirino T, Schillaci G. Waist circumference and body mass index in HIV infection. HIV Med. 2011 Feb;12(2):124-125.
Stelzl E, Ciesek S, Cornberg M, et al. Reliable quantification of plasma HDV-RNA is of paramount importance for treatment monitoring: a European multicenter study. J Clin Virol. 2021 Sep;142:104932.
Le Gal F, Brichler S, Drugan T, et al. Genetic diversity and worldwide distribution of the deltavirus genus: a study of 2152 clinical strains. Hepatology. 2017;66(6):1826-1841.
Karimzadeh H, Usman Z, Frishman D, Roggendorf M. Genetic diversity of hepatitis D virus genotype-1 in Europe allows classification into subtypes. J Viral Hepat. 2019;26(7):900-910.
Gaeta GB, Stroffolini T, Chiaramonte M, et al. Chronic hepatitis D: a vanishing disease? A multicenter Italian study. Hepatology. 2000;2000(32):824-827.
Beguelin C, Moradpour D, Sahli R, et al. Swiss HIV cohort study. Hepatitis delta-associated mortality in HIV/HBV-coinfected patients. J Hepatol. 2017 Feb;66(2):297-303.
Schaper M, Rodriguez-Frias F, Jardi R, et al. Quantitative longitudinal evaluations of hepatitis delta virus RNA and hepatitis B virus DNA shows a dynamic, complex replicative profile in chronic hepatitis B and D. J Hepatol. 2010;52:658-664.
Su C, Huang Y, Huo T, et al. Genotypes and viremia of hepatitis B and D viruses are associated with outcomes of chronic hepatitis D patients. Gastroenterology. 2006;130(6):1625-1635.
Hughes SA, Wedemeyer H, Harrison PM. Hepatitis Delta virus. Lancet. 2011;378(9785):73-85.
Jeyarajan AJ, Chhung RT. Insights into the pathoplysiology of liver disease in HCV/HIV: does it end with HCV cure? J Infect Dis. 2020;222(suppl 9):S802-S813. doi:10.1093/infdis/jiaa279
Yen DW, Soriano V, Barreiro P, Sherman KE. Triple threat: HDV, HBV, HIV coinfection. Clin Liver Dis. 2023;27:955-972.
Soriano V, Barreiro P, Martín-Carbonero L, Castellares C, Ruiz-Sancho A, Labarga P, Ramos B, Gonzalez-Lahoz J. Treatment of chronic hepatitis B or C in HIV-infected patients with dual viral.
Thio C, Seaberg E, Skolasky R, et al. HIV-1, hepatitis B virus, and risk of liver-related mortality in the multicenter cohort study (MACS). Lancet. 2002;360:1921-1926.
Mangia A, Squillante MM, Fraticelli F, et al. HDV RNA levels and progression of Hepatitis Delta infection: a 14 year follow up experience in Italy. Cell. 2023;12(10):1413.
Abbas Z, Sadik Memon M, Mithani H, Jafri V, Hamid S. Treatment of chronic hepatitis D patients with pegylated interferon: a real-world experience. Antivir Ther. 2014;19:463-468. doi:10.3851/IMP2728
Degasperi E, Anolli MP, Uceda Renteria SC, et al. Bulevirtide monotherapy for 48 weeks in patients with HDV-related compensated cirrhosis and clinically significant portal hypertension. J Hepatol. 2022;77(6):1525-1531.
Wedemeye H, Aleman S, Brunetto MR, et al. For the MYR 301 study group: a phase 3, randomized trial of Bulevirtide in chronic hepatitis D. N Engl J Med. 2023;389:22-32. doi:10.1056/NEJMoa2213429
Lampertico P, Roulot D, Wedermeyer H. Bulevirtide with or without pegIFNα for patients with compensated chronic hepatitis delta: from clinical trials to real-world studies. J Hepatol. 2022;77(5):1422-1430. doi:10.1016/j.jhep.2022.06.010
European Association for the Study of the liver. EASL clinical practice guidelines on hepatitis delta virus. J Hepatol. 2023;79:433-460.
Le Gal F, Gault E, Ripauit MP, et al. Eight major clade for hepatitis delta virus. Emerg Infect Dis. 2006;12:1447-1450.